Abiomed (ABMD) Tops Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year
October 28, 2021 7:00 AM EDTDANVERS, Mass.--(BUSINESS WIRE)-- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended September 30, 2021.
Q2 financial summary and operational highlights:
Revenue for the quarter totaled $248.1 million, an increase of 18% compared to $209.8 million during the same period of the prior fiscal year. Worldwide Impella® heart pump product revenue for the quarter totaled $235.8 million, an increase of 18% compared to $199.7 million during the same period of the prior fiscal year. U.S. Impella product revenue for... More